Loading: 100%
Axovant Sciences Ltd. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees (as per )no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker AXONno data available
Financial year endsFY ends End of Marchno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 170,07,515,022,530,0
datesClosing price (adj.)
13.10.20176.18
11.10.20176.54
04.10.20177.73
27.09.20176.99
20.09.201726.20
13.09.201719.83
06.09.201719.97
30.08.201719.74
23.08.201719.65
16.08.201721.80
09.08.201722.58
02.08.201723.28
26.07.201721.97
19.07.201723.06
12.07.201723.63
05.07.201723.17
27.06.201722.41
20.06.201723.12
13.06.201722.51
06.06.201722.21
30.05.201720.88
23.05.201722.91
16.05.201721.83
09.05.201722.91
02.05.201724.94
25.04.201723.09
18.04.201721.26
11.04.201720.25
04.04.201715.30
28.03.201714.69
21.03.201714.31
14.03.201713.99
07.03.201712.90
28.02.201712.71
21.02.201712.11
14.02.201711.74
07.02.201712.91
31.01.201712.25
24.01.201712.26
17.01.201712.31
10.01.201712.98
03.01.201712.30
27.12.201612.42
19.12.201612.62
12.12.201613.64
05.12.201614.00
28.11.201614.01
21.11.201613.48
14.11.201613.38
07.11.201612.02
31.10.201612.31
24.10.201613.81
17.10.201612.98
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
6.18n/a
Market Capitalisation
in million USD
664n/a
Enterprise Value
in million USD
418n/a
Common Shares Outstanding
as per Jun 30, 2017
107,473,925n/a
Preferred Shares Outstanding
as per Jun 30, 2017
n/a
Average Basic Shares Outstanding
TTM
100,988,469n/a
Average Diluted Shares Outstanding
TTM
100,971,427n/a
Index Membership
n/a
Business Summary
Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
no data available
Key Financials & Ratios (all figures TTM as per Jun 30, 2016, million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income -208n/a
EBITDA -207n/a
Net Profit -212n/a
Balance Sheet
Cash and Cash Equivalents 298n/a
Receivables 0n/a
Total Current Assets 307n/a
PP&E 2n/a
Total Assets 309n/a
Accounts Payable 9n/a
Current Debt 0n/a
Total Current Liabilities 51n/a
Long-Term Debt 52n/a
Total Liabilities 103n/a
Total Equity 206n/a
Cash Flow
Depreciation & Amortisation 1n/a
Change in Working Capital 29n/a
Operating Cash Flow -141n/a
Net Change in PP&E and Intangibles -2n/a
Investing Cash Flow -2n/a
Dividends Paid 0n/a
Financing Cash Flow 189n/a
Total Change in Cash 45n/a
Free Cash Flow -181n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity -102.9%n/a
Return on Assets -68.7%n/a
Per Share Figures
Basic EPS -2.10n/a
Diluted EPS -2.10n/a
Sales per Share 0.00n/a
Book Value per Share 2.04n/a
FCF per Share -1.80n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio -2.94n/a
Price to Sales Ratio n/a
Price to Book Value 3.03n/a
Price to Free Cash Flow -3.44n/a
Valuation Metrics
EV/EBITDA -2.02n/a
EV/Sales n/a
Book to Market Value 0.31n/a
Other Ratios
Current Ratio 600.8%n/a
Liabilities to Equity Ratio 49.9%n/a
Debt to Assets Ratio 16.8%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '15FY '16
Revenue
0
0
Sales & Services Revenue
0
0
Financing Revenue
0
0
Other Revenue
0
0
Cost of revenue
0
0
Cost of Goods & Services
0
0
Cost of Financing Revenue
0
0
Cost of Other Revenue
0
0
Gross Profit
0
0
Other Operating Income
0
0
Operating Expenses
-133
-180
Selling, General & Administrative
-57
-46
Selling & Marketing
0
0
General & Administrative
0
0
Research & Development
-77
-135
Depreciation & Amortization
0
0
Provision For Doubtful Accounts
0
0
Other Operating Expense
0
0
Operating Income (Loss)
-133
-180
Non-Operating Income (Loss)
0
-1
Interest Expense, net
0
-1
Interest Expense
0
0
Interest Income
0
0
Other Investment Income (Loss)
0
0
Foreign Exchange Gain (Loss)
0
0
Income (Loss) from Affiliates
0
0
Other Non-Operating Income (Loss)
0
0
Pretax Income (Loss), Adjusted
-133
-182
Abnormal Gains (Losses)
0
0
Acquired In-Process R&D
0
0
Merger / Acquisition Expense
0
0
Abnormal Derivatives
0
0
Disposal of Assets
0
0
Early extinguishment of Debt
0
0
Asset Write-Down
0
0
Impairment of Goodwill & Intangibles
0
0
Sale of Business
0
0
Legal Settlement
0
0
Restructuring Charges
0
0
Sale of and Unrealized Investments
0
0
Insurance Settlement
0
0
Other Abnormal Items
0
0
Pretax Income (Loss)
-133
-182
Income Tax (Expense) Benefit, net
0
1
Current Income Tax
0
0
Deferred Income Tax
0
0
Tax Allowance/Credit
0
0
Income (Loss) from Affiliates, net of taxes
0
0
Income (Loss) from Continuing Operations
-133
-181
Net Extraordinary Gains (Losses)
0
0
Discontinued Operations
0
0
XO & Accounting Charges & Other
0
0
Income (Loss) Including Minority Interest
-133
-181
Minority Interest
0
0
Net Income
-133
-181
Preferred Dividends
0
0
Other Adjustments
0
0
Net Income Available to Common Shareholders
-133
-181
Remarks
restated on Jun 13, 2017 n/a
calculated values,
restated on Jun 13, 2017 n/a
calculated values,
Balance SheetBS data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '15FY '16
Assets
Cash, Cash Equivalents & Short Term Investments
276
213
Cash & Cash Equivalents
276
213
Short Term Investments
0
0
Accounts & Notes Receivable
0
0
Accounts Receivable, Net
0
0
Notes Receivable, Net
0
0
Unbilled Revenues
0
0
Inventories
0
0
Raw Materials
0
0
Work In Process
0
0
Finished Goods
0
0
Other Inventory
0
0
Other Short Term Assets
6
7
Prepaid Expenses
5
6
Derivative & Hedging Assets
0
0
Assets Held-for-Sale
0
0
Deferred Tax Assets
0
0
Income Taxes Receivable
1
1
Discontinued Operations
0
0
Miscellaneous Short Term Assets
0
0
Total Current Assets
282
220
Property, Plant & Equipment, Net
0
0
Property, Plant & Equipment
0
0
Accumulated Depreciation
0
0
Long Term Investments & Receivables
0
0
Long Term Investments
0
0
Long Term Marketable Securities
0
0
Long Term Receivables
0
0
Other Long Term Assets
0
3
Intangible Assets
0
0
Goodwill
0
0
Other Intangible Assets
0
0
Prepaid Expense
0
0
Deferred Tax Assets
0
3
Derivative & Hedging Assets
0
0
Prepaid Pension Costs
0
0
Discontinued Operations
0
0
Investments in Affiliates
0
0
Miscellaneous Long Term Assets
0
0
Total Noncurrent Assets
0
3
Total Assets
282
223
Liabilities and owners' equity
Payables & Accruals
9 8941000
43 43347000
Accounts Payable
1 622000
9 8551000
Accrued Taxes
0 0
0 0
Interest & Dividends Payable
0 0
0 0
Other Payables & Accruals
8 8319000
35 34796000
Short Term Debt
0 0
0 0
Short Term Borrowings
0 0
0 0
Short Term Capital Leases
0 0
0 0
Current Portion of Long Term Debt
0 0
0 0
Other Short Term Liabilities
7 6814000
3 2919000
Deferred Revenue
0 0
0 0
Derivatives & Hedging
0 0
0 0
Deferred Tax Liabilities
0 0
0 0
Discontinued Operations
0 0
0 0
Miscellaneous Short Term Liabilities
7 6814000
3 2919000
Total Current Liabilities
16 15755000
46 46266000
Long Term Debt
0 0
51 51436000
Long Term Borrowings
0 0
0 0
Long Term Capital Leases
0 0
0 0
Other Long Term Liabilities
0 0
0 0
Accrued Liabilities
0 0
0 0
Pension Liabilities
0 0
0 0
Pensions
0 0
0 0
Other Post-Retirement Benefits
0 0
0 0
Deferred Compensation
0 0
0 0
Deferred Revenue
0 0
0 0
Deferred Tax Liabilities
0 0
0 0
Derivatives & Hedging
0 0
0 0
Discontinued Operations
0 0
0 0
Miscellaneous Long Term Liabilities
0 0
0 0
Total Noncurrent Liabilities
0 0
51 51436000
Total Liabilities
16 15755000
98 97702000
Preferred Equity
0 0
0 0
Share Capital & Additional Paid-In Capital
421 420935000
460 459602000
Common Stock
0 0
0 0
Additional Paid in Capital
0 0
0 0
Other Share Capital
0 0
0 0
Treasury Stock
0 0
0 0
Retained Earnings
-154 -154192000
-335 -335143000
Other Equity
0 0
0 378000
Equity Before Minority Interest
267 266743000
125 124837000
Minority Interest
0 0
0 0
Total Equity
267 266743000
125 124837000
Total Liabilities & Equity
282 282498000
223 222539000
Remarks restated on Jun 13, 2017 n/a restated on Aug 7, 2017 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '15FY '16
Net Income/Starting Line
-133
-181
Net Income
0
0
Net Income From Discontinued Operations
0
0
Other Adjustments
0
0
Depreciation & Amortization
0
0
Non-Cash Items
77
34
Stock-Based Compensation
0
0
Deferred Income Taxes
0
0
Other Non-Cash Adjustments
0
0
Change in Working Capital
2
34
(Increase) Decrease in Accounts Receivable
0
0
(Increase) Decrease in Inventories
0
0
Increase (Decrease) in Accounts Payable
0
0
Increase (Decrease) in Other
0
0
Net Cash From Discontinued Operations (operating)
0
0
Cash from Operating Activities
-53
-112
Change in Fixed Assets & Intangibles
0
0
Disposition of Fixed Assets & Intangibles
0
0
Disposition of Fixed Assets
0
0
Disposition of Intangible Assets
0
0
Acquisition of Fixed Assets & Intangibles
0
0
Purchase of Fixed Assets
0
0
Acquisition of Intangible Assets
0
0
Other Change in Fixed Assets & Intangibles
0
0
Net Change in Long Term Investment
0
0
Decrease in Long Term Investment
0
0
Increase in Long Term Investment
0
0
Net Cash From Acquisitions & Divestitures
0
0
Net Cash from Divestitures
0
0
Cash for Acqusition of Subsidiaries
0
0
Cash for Joint Ventures
0
0
Net Cash from Other Acquisitions
0
0
Other Investing Activities
-5
0
Net Cash From Discontinued Operations (investing)
0
0
Cash from Investing Activities
-5
0
Dividends Paid
0
0
Cash From (Repayment of) Debt
336
49
Cash From (Repayment of) Short Term Debt, net
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
Repayments of Long Term Debt
0
0
Cash From Long Term Debt
0
0
Cash From (Repurchase of) Equity
0
0
Increase in Capital Stock
0
0
Decrease in Capital Stock
0
0
Other Financing Activities
-1
0
Net Cash From Discontinued Operations (financing)
0
0
Cash from Financing Activities
335
49
Net Cash Before Disc. Operations and FX
276
-64
Change in Cash from Disc. Operations and Other
0
0
Net Cash Before FX
276
-64
Effect of Foreign Exchange Rates
0
0
Net Changes in Cash
276
-64
Remarks
restated on Jun 13, 2017 n/a
calculated values,
restated on Jun 13, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo